The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKooth Plc Regulatory News (KOO)

Share Price Information for Kooth Plc (KOO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 294.00
Bid: 292.00
Ask: 296.00
Change: -1.00 (-0.34%)
Spread: 4.00 (1.37%)
Open: 295.00
High: 295.00
Low: 294.00
Prev. Close: 295.00
KOO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half year results

21 Sep 2021 07:00

RNS Number : 3579M
Kooth PLC
21 September 2021
 

 

Kooth plc

("Kooth or the "Company" or the "Group")

 

21 September 2021

 

Half year results

Momentum and growth; comfortably in line with FY expectations

 

Kooth (AIM: KOO), a leading digital mental health platform provider, announces unaudited half year results for the six months ended 30 June 2021.

 

Strategic Highlights

Children and Young People: we are contracted by more than 90% of NHS England CCGs (2020: 85%).

Kooth Adult (early intervention for adults, via NHS) 'whole population' total contracts doubled in H1 vs 2020. Kooth Adult now represents £1.5m ARR.

Kooth Work (employee wellbeing) growth into membership-based businesses included, for example, the Chartered Management Institute.

Ongoing investment in talent, technology, and outcome measures to deliver personalised, effective care.

 

Financial Highlights

Revenues up 35% to £8.0m (H1 2020: £5.9m).

Robust balance sheet with net cash of £8.8m provides capacity for investment.

Annual Recurring Revenue (ARR) up 23% to £16.6m.

Adjusted EBITDA up 135% to £1.1m.

High quality of earnings:

o More than 90% revenues from contracts of 12 months or longer.

o More than 95% customer retention by revenue.

 

Tim Barker, Chief Executive of Kooth said:

"With NHS waiting lists for mental health now totalling 1.8m people, the imperative and opportunity to provide high quality support via digital has never been clearer. Kooth's growth and performance reflects good progress on our mission to make effective, personalised digital mental health care available to all. In the last six months, Kooth has further strengthened its position as the leading digital platform supporting children and young people via the NHS, and we are delivering on our objectives to expand support to Adults via the NHS and Corporates.

 

"Our robust balance sheet enables us to invest to meet long-term, increasing demand for Kooth's services. We will continue this investment in our talent and technology to enable us to scale up to tackle what is one of the world's biggest challenges. Looking to the full year outturn, we expect Group revenue to be comfortably in line with expectations."

 

 

 

For further information, please contact:

Kooth plc

 

Tim Barker, Chief Executive

Sanjay Jawa, Chief Financial Officer

investorrelations@kooth.com 

 

Panmure Gordon, Nominated Adviser and Broker

 

Corporate Finance:

Dominic Morley, Ailsa MacMaster

Corporate Broking:

Erik Anderson

+44 (0) 20 7886 2500

FTI Consulting

 

Jamie Ricketts / Alex Shaw / Usama Ali

kooth@fticonsulting.com

 

Notes to Editors:

About Kooth

Kooth (AIM:KOO) is the UK's leading digital mental health platform, established to provide accessible and safe spaces for everyone to achieve better mental health. The Company's online platform is clinically robust and accredited to provide a range of therapeutic support and interventions. All services are predicated on easy access to make early intervention and prevention a reality.

 

Kooth offers three services:

 

Kooth is commissioned in over 90% of the NHS's clinical commissioning group areas across the country. It is a fully safeguarded and pre-moderated community with a library of peer and professional created content, alongside access to experienced online counsellors. There are no thresholds for support and no waiting lists. Currently, Kooth sees over 3,000 logins a day.

Kooth Adult operates across distinct locations and serves specific cohorts, including parents, teachers, victims of crime and those who have suffered from or continue to experience domestic violence.

Kooth Work is a corporate service, aimed specifically at employers to support the wellbeing of their employees, providing confidential and anonymous access to a wellbeing community, counselling, content and self-help tools. Kooth Work provides valuable, anonymous insights into the wellbeing of the workforce so that employers can identify specific areas of improvement for their wellbeing strategy.

 

 

 

Chief Executive's Review

Momentum and progress

 

The Group continues to make good progress against its strategic priorities: growing its leadership position in supporting children and young people via the NHS, and expanding to support Adults via the NHS and Corporate market.

 

This was reflected in revenue growth of 35% and adjusted EBITDA growth of 135%.

 

We've seen further contract expansion and high customer retention across the business, retaining 95% of our customers and delivering net revenue retention of 116%. In the Children and Young Persons market we now cover more than 90% of Clinical Commissioning Groups (CCGs) in England, Our Adult platform via the NHS has seen good momentum, doubling the total number of 'whole populations' contracts we operate to 16. In the corporate market, new customer partnerships with the Chartered Management Institute and Capita demonstrate the opportunity for innovators to embed employee mental wellbeing into their business model.

 

In addition, the London School of Economics published an independent study which found that Kooth's self-help activities are beneficial to 96% of users. Kooth's peer support community helps reduce stigma, with 77% of users more likely to seek support for their mental health after engaging.

 

Strategy

Kooth has a clear four-pillar growth strategy to support the increasing demand for mental health services in the public and private sector, all underpinned by investments in our technology platform and clinical operating model:

 

1. Continue to scale Kooth to support young people

2. Replicate our success into the adult public sector market

3. Bring the benefits of Kooth to every workplace

4. Expand into international markets.

 

Children and Young People

Kooth is the Group's service for the provision of free at the point of use services for children and young people (CYP)

 

Kooth is now contracted by more than 90% of NHS England CCGs to support the mental health needs of children and young people (FY20: 85%). This includes full coverage across all 32 London boroughs, seven Welsh Health Boards, and our first two contracts in Scotland.

 

Kooth Adult

Kooth Adult provides early intervention support to adults via the NHS.The Group's focus on 'whole population' contracts is building momentum, adding eight commissions in the first half of 2021 to the five that were contracted in 2020. In addition, we have seen an increase in average contract size. Adult ARR is now £1.5m.

 

Kooth Work

Kooth Work supports corporates with employee wellbeing

 

Kooth Work continues to expand to help employees reach their full potential at work. As announced in April 2021, the Chartered Management Institute has partnered with Kooth to provide free mental health support to their UK members. In addition, Kooth has been commissioned by Capita to provide mental health support to job-seekers as part of Capita's programme to help those made unemployed as a result of COVID find work. This demonstrates the potential to integrate mental health support alongside other services to reduce stigma, and increase reach and impact.

 

Investing for long-term growth

 

Kooth is investing in its talent and technology platforms to drive its growth strategy and meet increasing demand for digital mental health support and tools. This is intended to capture the long-term market opportunity available both in the UK and internationally.

 

Key progress in H1 includes:

 

Evidencing the therapeutic outcomes for Kooth is key in advancing the business case for digital mental health care. However, digital isn't just about mirroring traditional face-to-face support, it enables entirely new care models, such as a drop-in chat session. To prove the impact of this, Kooth collaborated with the CORC (Child Outcomes Research Consortium) to independently validate a new therapeutic measure called SWAN-0M (Session Wants and Needs Outcome Measure) which shows that 72% of users achieve a good outcome from a single chat session on Kooth.

 

As a first step into supporting international markets, Kooth and the Department of International Trade have developed and are delivering a pilot project in South Africa, with support from the Western Cape Education Department and British Council South Africa to demonstrate the impact of the Kooth service in supporting Young People and strengthening educational professionals' confidence in managing mental health at school.

 

Current trading and outlook

Kooth will continue to invest in its technology platform, systems and talent in the second half of 2021. This is part of Kooth's strategy to meet long-term demand for digital mental health services.

 

With closing annual recurring revenue at 30 June 2021 of £16.6m the Board expects Kooth to be comfortably in line with revenue expectations for the full year. This reflects Kooth's good progress against its priorities for the first half which included maintaining its leadership position in supporting children and young people via the NHS as well as doubling the number of Kooth Adult 'whole population' contracts.

 

Tim Barker

Chief Executive

21 September 2021

 

 

 

Chief Financial Officer's review

 

The Group has had a positive first half of the year and as reported we expect revenue to be comfortably in line with market expectations for the full year.

 

The Group has seen an increase across revenue, annual recurring revenue, gross margin, EBITDA and operating profit for the half year ended 30 June 2021 in comparison to the six months ended 30 June 2020.

 

Revenue

Revenue increased by 35% to £8.0 million (2020 H1: £5.9 million), Annual Recurring Revenue grew by 23% to £16.6 million (2020 H1: £13.5 million), with 22 new contracts obtained in the first half of 2021 across all service types in addition to a number of contract uplifts. Churn for the period was less than 5%.

 

Gross Profit

Gross Profit as a percentage of turnover increased during the period by 3.6 percentage points from 59.7% to 63.3%. This was primarily an accounting change (2.5 percentage points) reclassifying certain clinical costs from direct to indirect costs. This is an ongoing change. To a lesser extent we continued to see some lower direct costs as a result of lockdown as most engagement meetings continued to be conducted virtually. This led to a reduction in travel and subsistence costs as well as allowing the team to reach more users.

 

Adjusted EBITDA

Adjusted EBITDA in the period increased from £0.5m to £1.1m with increased gross profit offset by higher administrative expenses including the costs of being a public company and the receipt in 2020 of £0.5m of other operating income relating to a government research grant. The total charge for share based payments in the period was £0.3m (2020 H1: £0.1m). This increase reflects the awards made under the senior and all staff 2020 Long Term Incentive Plan following our IPO.

 

Exceptional items

No exceptional costs were incurred during the period (2020 H1: £0.4m). Prior year costs in the period to 30 June related to pre IPO related expenses.

 

Taxation

There has been no corporation tax charge recognised in the six months to 30 June 2021 due to accumulated losses combined with the overall current year position (2020 H1: £nil). The tax credit for the six months ended 30 June 2021 and 2020 relate to Research and Development expenditure credits in addition to the movement in the deferred tax asset.

 

Profit after tax

The Group achieved a profit after tax for the period of £0.04 million (2020 H1: £0.8 million loss).

 

Headcount

Headcount has increased from the year end by 46 staff members across the Group to 352, with an investment drive to build out our Service Delivery and Product and Technology teams as well as clinical and commercial staff across the wider business to drive our growth strategies.

 

Balance Sheet

Kooth has maintained a robust balance sheet following the successful IPO in September 2020 which raised £16m prior to expenses and repayment of debt, with net cash at 30 June 2021 of £8.8m (2020 H1: £0.6m), demonstrating good underlying cash generation and ensuring capacity to invest in the Group's long-term growth.

 

Cash flow and financing

Cash generation during the six months was £1.0 million (2020 H1: £0.4 million), driven by increased revenues and gross profit including an increased number of customers paying in advance.

 

After repaying all debts in the second half of 2020, the Group is debt free (2020 H1: £6.4 million).

 

The Group is committed to investment following the IPO listing and as a result capital expenditure increased 96% to £1.5 million (2020 H1: £0.8 million), with increases to our Product and Technology teams and project costs.

 

 

Sanjay Jawa

Chief Financial Officer

21 September 2021

 

Condensed Consolidated Statement of Comprehensive Income

For the six months ended 30 June 2021

 

 

Note

Six months ended 30 June 2021

Unaudited

 

Six months ended 30 June 2020

Unaudited

 

Year ended 31 December 2020

Audited

Continuing operations

 

 

£'000

 

£'000

 

£'000

 

 

 

 

 

 

 

 

Revenue

 

9

7,964

 

5,901

 

13,012

Cost of sales

 

 

(2,925)

 

(2,380)

 

(5,091)

 

 

 

 

 

 

 

 

Gross profit

 

 

5,039

 

3,521

 

7,921

 

 

 

 

 

 

 

 

Administrative expenses

 

 

(5,184)

 

(4,715)

 

(10,049)

Other operating income

 

 

-

 

497

 

497

 

 

 

 

 

 

 

 

Operating Loss

 

 

(145)

 

(697)

 

(1,631)

 

 

 

 

 

 

 

 

Analysed as:

 

 

 

 

 

 

 

Adjusted EBITDA

 

 

1,130

 

477

 

934

Depreciation & amortisation

 

13

(970)

 

(682)

 

(1,498)

Exceptional items

 

 

-

 

(411)

 

(580)

Share based payment expense

 

 

(305)

 

(101)

 

(507)

Gain on disposal of subsidiary

 

 

-

 

20

 

20

 

 

 

 

 

 

 

 

Operating Loss

 

 

(145)

 

(697)

 

(1,631)

 

 

 

 

 

 

 

 

Interest paid

 

 

-

 

(224)

 

(314)

 

 

 

 

 

 

 

 

Loss before tax

 

 

(145)

 

(921)

 

(1,945)

 

 

 

 

 

 

 

 

Tax

 

 

183

 

150

 

467

 

 

 

 

 

 

 

 

Profit/(Loss) after tax from continuing operations

 

 

38

 

(771)

 

(1,478)

Profit/(Loss) after tax from discontinued operations

 

 

-

 

1

 

1

 

 

 

 

 

 

 

 

Total comprehensive profit/(loss) for the period

 

 

38

 

(770)

 

(1,477)

 

 

 

 

 

 

 

 

Profit/(Loss) per share - basic (£)

 

11

0.00

 

(0.04)

 

(0.06)

On continuing operations

 

 

0.00

 

(0.04)

 

(0.06)

On discontinued operations

 

 

-

 

0.00

 

0.00

 

 

 

 

 

 

 

 

Profit/(Loss) per share - diluted (£)

 

 

0.00

 

(0.03)

 

(0.06)

On continuing operations

 

 

0.00

 

(0.03)

 

(0.06)

On discontinued operations

 

 

-

 

0.00

 

0.00

 

 

 

 

 

 

 

 

 

 

Condensed Consolidated Balance Sheet

As at 30 June 2021

 

 

 

Note

30 June 2021

Unaudited

 

30 June 2020

Unaudited

 

31 December 2020

Audited

 

 

 

£'000

 

£'000

 

£'000

Assets

 

 

 

 

 

 

 

Non-current assets

 

 

 

 

 

 

 

Goodwill

 

 

511

 

511

 

511

Development costs

 

13

3,131

 

2,473

 

2,615

Right of use asset

 

 

10

 

20

 

14

Property, plant and equipment

 

 

139

 

164

 

157

Deferred tax

 

 

156

 

-

 

133

 

 

 

 

 

 

 

 

Total non-current assets

 

 

3,947

 

3,168

 

3,430

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

Trade & other receivables

 

 

2,083

 

3,451

 

2,097

Contract assets

 

 

190

 

362

 

107

Cash & cash equivalents

 

 

8,799

 

601

 

7,823

 

 

 

 

 

 

 

 

Total current assets

 

 

11,072

 

4,414

 

10,027

 

 

 

 

 

 

 

 

Total assets

 

 

15,019

 

7,582

 

13,457

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

Trade payables

 

 

(327)

 

(634)

 

(275)

Contract liabilities

 

 

(1,838)

 

(723)

 

(619)

Borrowings

 

 

-

 

(6,402)

 

-

Lease liability

 

 

(10)

 

(22)

 

(17)

Accruals and other creditors

 

 

(808)

 

(1,716)

 

(866)

Deferred tax

 

 

-

 

(31)

 

-

Tax liabilities

 

 

(859)

 

(1,556)

 

(827)

 

 

 

 

 

 

 

 

Total current liabilities

 

 

(3,842)

 

(11,084)

 

(2,604)

 

 

 

 

 

 

 

 

Net current assets

 

 

7,230

 

(6,670)

 

7,423

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Assets / (Liabilities)

 

 

11,177

 

(3,502)

 

10,853

 

 

 

 

 

 

 

 

 

(continued)

 

 

Equity

 

 

 

 

 

 

 

Share capital

 

 

1,653

 

-

 

1,653

Share premium Account

 

 

14,229

 

4

 

14,229

P&L reserve

 

 

(1,531)

 

(3,607)

 

(1,569)

Share-based payment reserve

 

 

815

 

101

 

529

Capital redemption reserve

 

 

115

 

-

 

115

Merger reserve

 

 

(4,104)

 

-

 

(4,104)

 

 

 

 

 

 

 

 

Total equity

 

 

11,177

 

(3,502)

 

10,853

 

Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2021

 

 

Six months ended 30 June 2021

Unaudited

 

Six months ended 30 June 2020

Unaudited

 

Year ended 31 December 2020

Audited

 

 

£'000

 

£'000

 

£'000

Cash flows from operating activities

 

 

 

 

 

 

 

 

 

 

 

 

 

Profit/(Loss) for the period from continuing operations

 

38

 

(771)

 

(1,478)

Profit/(Loss) for the period from discontinued operations

 

-

 

1

 

1

Adjustments:

 

 

 

 

 

 

Depreciation & amortisation

 

970

 

682

 

1,498

Income tax received

 

-

 

-

 

268

Share based payment expense

 

305

 

101

 

507

Interest expense

 

-

 

224

 

314

Tax income recognised

 

(183)

 

(150)

 

(466)

Gain on Disposal

 

-

 

(20)

 

(20)

 

 

 

 

 

 

 

Movements in working capital:

 

 

 

 

 

 

(Increase)/decrease in trade and other receivables

 

69

 

(1,530)

 

132

Increase/(decrease) in trade and other payables

 

1,245

 

1,557

 

(396)

Net cashflow from operating activity

 

2,444

 

94

 

360

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

 

Purchase of property, plant and equipment

 

(34)

 

(68)

 

(107)

Additions to intangible assets

 

(1,430)

 

(684)

 

(1,505)

Net cash used in investing activities

 

(1,464)

 

(752)

 

(1,612)

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

Proceeds from issue of capital

 

-

 

2

 

16,000

Cost incurred on issue of capital

 

-

 

-

 

(1,378)

Receipt/(Repayment) of borrowings

 

-

 

1,044

 

(4,249)

Interest paid

 

-

 

-

 

(1,444)

Lease payments

 

(4)

 

(16)

 

(81)

Net cash from financing activities

 

(4)

 

1,030

 

8,848

 

 

 

 

 

 

 

Net increase/(decrease) in cash and cash equivalents

 

976

 

372

 

7,596

Cash and cash equivalents at the beginning of the period

 

7,823

 

229

 

227

Cash and cash equivalents at the end of the period

 

8,799

 

601

 

7,823

 

Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2021

 

 

Share Capital

Share Premium

Share Based Payment Reserve

P&L Reserve

Capital Redemption Reserve

Merger reserve

Total Equity

 

 

 

 

 

 

 

 

 

Balance at 1 January 2020

 

-

4

-

(2,837)

-

-

(2,833)

 

 

 

 

 

 

 

 

 

Share based payments

 

-

-

101

-

-

-

101

Total comprehensive income for the period

 

-

-

-

(770)

-

-

(770)

As at 30 June 2020

 

-

4

101

(3,607)

-

-

(3,502)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at 1 July 2020

 

-

4

101

(3,607)

-

-

(3,502)

 

 

 

 

 

 

 

 

 

Issue of share capital

 

400

14,225

-

-

-

 

14,625

Share for share exchange

 

3,989

-

-

-

115

(4,104)

-

Capital reduction

 

(2,736)

-

-

2,736

-

-

-

Share based payments

 

-

-

428

-

-

-

428

Deferred tax

 

-

-

-

10

-

-

10

Total comprehensive income for the period

 

-

-

-

(708)

-

-

(708)

As at 31 December 2020

 

1,653

14,229

529

(1,569)

115

(4,104)

10,853

 

 

 

 

 

 

 

 

 

Balance at 1 January 2021

 

1,653

14,229

529

(1,569)

115

(4,104)

10,853

 

 

 

 

 

 

 

 

 

Share based payments

 

-

-

286

-

-

-

286

Total comprehensive income for the period

 

-

-

-

38

-

-

38

As at 30 June 2021

 

1,653

14,229

815

(1,531)

115

(4,104)

11,177

 

Notes to the half year financial statements

 

1. General information 

The unaudited interim consolidated financial statements for the six months ended 30 June 2021 and the six months ended 30 June 2020 do not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006. Statutory accounts for the year ended 31 December 2020 were approved by the Board of Directors on 13 April 2021 and delivered to the Registrar of Companies. The auditor's report on those accounts was unqualified, did not contain an emphasis of matter paragraph and did not contain any statement under Section 498 (2) or (3) of the Companies Act 2006.

 

These condensed half year financial statements were approved for issue by the Board of Directors on 21 September 2021. 

2. Basis of preparation

 

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 for the year ended 31 December 2020.

 

Trading for the half year ended 30 June 2021 was comfortably in line with the Board's expectations, and this is expected to be the case for the full year. Further details are given in the Chief Executive report.

 

The Group is in a net asset position of £11.2 million as at 30 June 2021 (2020: net liabilities of £3.5 million) and has no debt facilities in place. Management have prepared forecasts up until 12 months from the date of approval of these financial statements which have been approved by the Board, and after enquiry and review of these forecasts and other available financial information, the Directors have formed the conclusion that the Group has adequate resources to continue to operate for the foreseeable future and that it is therefore appropriate to continue to adopt the going concern basis of accounting in the preparation of these interim condensed consolidated half year financial statements.

 

The financial information is presented in sterling, which is the functional currency of Kooth Group. All financial information presented has been rounded to the nearest thousand.

 

3. Accounting policies

 

The accounting policies applied in these interim financial statements are the same as those applied in the Group's annual report and accounts for the year ended 31 December 2020.

Current taxes on income in the half year period are accrued using the tax rates that would be applicable to expected total annual profits.

Deferred taxes on income are calculated based on the standard rates that are enacted as at the balance sheet date.

 

 

4. Critical accounting judgements and key sources of estimation uncertainty

 

Any critical accounting judgements and key sources of estimation uncertainty that carry a significant risk of material change to the carrying value of assets and liabilities within the next year are the same as those applied in the 2020 Group annual report.

 

5. Principal risks and uncertainties

 

The 2020 Group annual report and accounts describes the principal risks and uncertainties that could impact the Group's performance. These risks primarily relate to cyber security and clinical safety, with any risks relating to COVID-19 deemed to be not material given the industry in which the Group operates and the Group's business model. These remain unchanged since the annual report was published and are not expected to change for the remaining six months of the financial year.

 

The Group actively manages these risks through risk management procedures and actions are taken to mitigate risk wherever possible.

 

6. Financial risk management

 

The Group is exposed to financial risks including market risk, credit risk & liquidity risk. These interim condensed consolidated financial statements do not include all financial risk management information and disclosures required in the annual financial statements and therefore should be read in conjunction with the 2020 Group annual report and accounts.

 

7. Forward-looking statements

 

Certain statements in this half year report are forward looking. Although the Group believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. Because these statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements.

 

8. Segmental reporting

 

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the executive directors that make strategic decisions.

 

As Kooth plc's operations are all in one location within the United Kingdom, the Directors are of the opinion that the Group has only one reportable operating segment, this is in line with internal reporting provided to the executive directors.

 

9. Revenue analysis

 

Revenue has been derived from its principal activity wholly undertaken in the United Kingdom, and relates to the provision of online counselling services.

 

 

 

 

 

Six months ended 30 June 2021

Unaudited

 

Six months ended 30 June 2020

Unaudited

 

Year ended 31 December 2020

Audited

 

 

 

£'000

 

£'000

 

£'000

Revenue generated from counselling platform

 

 

7,964

 

5,901

 

13,012

 

 

10. Income tax expense

 

The income tax expense recognised reflects management estimates of the tax charge for the period and has been calculated using the estimated average tax rate of UK corporate tax for the financial year of 19% (2020: 19%).

 

11. Earnings per share (EPS)

 

The calculation of basic and diluted EPS is based on the following earnings and number of shares:

 

 

 

 

 

Six months ended 30 June 2021

Unaudited

 

Six months ended 30 June 2020

Unaudited

 

Year ended 31 December 2020

Audited

 

 

 

 

 

 

 

 

 

Basic

 

 

 

£'000

 

£'000

 

£'000

Earnings used in calculation of earnings per share:

 

 

 

 

 

 

 

 

On total losses attributable to equity holders of the parent

 

 

 

38

 

(770)

 

(1,477)

On continuing operations

 

 

 

38

 

(771)

 

(1,478)

On discontinued operations

 

 

 

 

 

1

 

1

 

 

 

 

 

 

 

 

 

Weighted average no. of shares (basic)

 

 

 

33,055,776

 

20,000,000

 

24,351,925

Weighted average no. of shares (diluted)

 

 

 

34,023,265

 

23,865,304

 

24,685,152

 

 

 

 

 

 

 

 

 

Shares in issue

 

 

 

2021

 

2020

 

2020

B shares in issue

 

 

 

-

 

5,055,776

 

-

Ordinary shares in issue

 

 

 

33,055,776

 

20,000,000

 

33,055,776

LTIP

 

 

 

967,489

 

-

 

999,681

 

 

 

 

 

 

 

 

 

Loss per share - Basic (£)

 

 

 

 

 

 

 

 

On total profits attributable to equity holders of the parent

 

 

 

0.00

 

(0.04)

 

(0.06)

On continuing operations

 

 

 

0.00

 

(0.04)

 

(0.06)

On discontinued operations

 

 

 

-

 

0.00

 

0.00

 

 

 

 

 

 

 

 

 

Loss per share - Diluted (£)

 

 

 

 

 

 

 

 

On total profits attributable to equity holders of the parent

 

 

 

0.00

 

(0.03)

 

(0.06)

On continuing operations

 

 

 

0.00

 

(0.03)

 

(0.06)

On discontinued operations

 

 

 

-

 

0.00

 

0.00

 

 

12. Dividends

 

The Group's intention in the short to medium term is to invest in order to deliver capital growth for shareholders. The Board has not recommended an interim dividend payment in respect of the six months ended 30 June 2021 (2020: £nil) and does not anticipate recommending a dividend within the next year, but may do so in future years.

 

13. Development costs

 

 

 

 

 

 

 

Development costs

 

 

 

£'000

Cost

 

 

 

At 1 January 2020

 

 

3,297

Additions

 

 

684

At 30 June 2020

 

 

3,981

Additions

 

 

846

At 31 December 2020

 

 

4,827

Additions

 

 

1,430

At 30 June 2021

 

 

6,257

 

 

 

 

Amortisation

 

 

 

At 1 January 2020

 

 

(895)

Amortisation

 

 

(613)

At 30 June 2020

 

 

(1,508)

Amortisation

 

 

(705)

At 31 December 2020

 

 

(2,213)

Amortisation

 

 

(913)

At 30 June 2021

 

 

(3,126)

 

 

 

 

Carrying amount

 

 

 

At 1 January 2020

 

 

2,402

At 30 June 2020

 

 

2,473

At 31 December 2020

 

 

2,615

At 30 June 2021

 

 

3,131

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR BSGDCLUDDGBG
12
Date   Source Headline
24th May 20247:00 amRNS2023 Annual Report and Notice of AGM
30th Apr 20247:00 amRNSDirectorate Change
23rd Apr 20247:00 amRNSInvestor Presentation via Investor Meet Company
26th Mar 20247:00 amRNSAnnual Financial Report
1st Mar 20247:00 amRNSBlock Listing Six Monthly Return
22nd Jan 20247:00 amRNSTrading Statement
9th Jan 20247:00 amRNSLaunch of California contract
14th Nov 202311:41 amRNSHolding(s) in Company
27th Oct 202310:19 amRNSAwards under Incentive Plan & PDMR dealing
16th Oct 20235:27 pmRNSHolding(s) in Company
16th Oct 20233:06 pmRNSHolding(s) in Company
11th Oct 202311:24 amRNSHolding(s) in Company
5th Oct 20236:25 pmRNSDirector/PDMR Shareholding
2nd Oct 20237:00 amRNSAppointment of Nominated Adviser and Broker
26th Sep 20232:07 pmRNSInvestor Presentation via Investor Meet Company
22nd Sep 20233:59 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSHalf-year Results
12th Sep 20232:11 pmRNSHolding(s) in Company
1st Sep 20237:00 amRNSBlock listing application
19th Jul 20237:18 amRNSInvestor Presentation via Investor Meet Company
4th Jul 202310:48 amRNSResult of Placing, PDMR Dealings & TVR
4th Jul 20237:01 amRNSProposed placing to raise approximately £10million
4th Jul 20237:00 amRNS$188m four year contract in California
29th Jun 202311:56 amRNSResult of 2023 AGM, update on California contract
23rd May 20231:58 pmRNSHolding(s) in Company
6th Apr 202310:55 amRNSInvestor Presentation via Investor Meet Company
4th Apr 20239:25 amRNSNotice of AGM
4th Apr 20237:00 amRNSFY22 Results
16th Mar 20232:05 pmRNSSecond Price Monitoring Extn
16th Mar 20232:00 pmRNSPrice Monitoring Extension
16th Mar 202311:05 amRNSSecond Price Monitoring Extn
16th Mar 202311:00 amRNSPrice Monitoring Extension
16th Mar 20237:00 amRNSSignificant US contract in California
19th Jan 20237:00 amRNSTrading Update
17th Jan 20237:00 amRNSInvestor Presentation
6th Dec 20226:15 pmRNSNotification of Transactions of Directors
9th Nov 20227:00 amRNSHolding(s) in Company
17th Oct 20224:41 pmRNSSecond Price Monitoring Extn
17th Oct 20224:35 pmRNSPrice Monitoring Extension
13th Oct 20227:00 amRNSContract with State of Pennsylvania formalised
27th Sep 20227:01 amRNSHalf Year Results
27th Sep 20227:00 amRNSSignificant US Contract Win
26th Jul 20227:00 amRNSTrading Statement
7th Jun 20223:11 pmRNSResult of AGM
13th May 20227:00 amRNSCapital Markets Day
31st Mar 20226:14 pmRNS2021 Annual Report and Notice of AGM
29th Mar 20227:00 amRNSFinal Results
16th Mar 20227:00 amRNSUpdate on strategic progress
20th Jan 20227:00 amRNSTrading Statement
29th Dec 20214:20 pmRNSHoldings in Company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.